Navigation Links
Lentigen Awarded $1.2 Million by U.S. Government Under the Qualifying Therapeutic Discovery Project
Date:11/3/2010

GAITHERSBURG, Md., Nov. 3, 2010 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that it will receive $1,235,306 in cash grants from the U.S. Government under the Patient Protection and Affordable Care Act.

Only companies with no more than 250 employees were eligible. Qualifying projects had to show reasonable potential to result in new therapies to treat areas of unmet medical need, prevent, detect, or treat chronic or acute disease and conditions, reduce long-term healthcare costs in the U.S., or significantly advance the goal of curing cancer within a 30-year period. 

In addition, preference was given to projects that showed the greatest potential to create and sustain high-quality, high-paying jobs in the U.S. and advance the country's competitiveness in the fields of life, biological, and medical sciences. Qualifying projects were eligible for either grants or tax credits.

"We are very pleased that 8 of the 9 applications that we submitted for review by the NIH and Treasury were approved and that the overall grant placed us among the top 5% of recipients in the nation. This provides further validation of our programs in cell therapies, vaccines and biotherapeutics," stated Tim Ravenscroft, CEO of Lentigen.  "As a small company operating in a difficult economic climate, these funds are very timely and will be invested in completion of our GMP manufacturing facility and the support of several of the therapeutic and vaccine programs submitted for consideration."

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and bioproduction applications. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing Lentiviral vector-based products across a broad spectrum of bench to clinical applications. Collaborations include The National Institutes of Health, PATH, IAVI, Harvard Medical School, Expression Therapeutics, Epixis SA, The University of Pennsylvania, The Johns Hopkins University, Case Western Reserve University, The Medical College of South Carolina, The University of Pittsburgh, the University of Minnesota, and The U.S. Army. For further information, visit www.lentigen.com.


'/>"/>
SOURCE Lentigen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Lentigen Awarded Phase I STTR Grant for Hunter Syndrome
2. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
3. Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
4. Lentigen Corporation Announces Relocation to New Facility
5. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
6. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
7. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
8. Federal nanotechnology renewal grant awarded to ASU faculty
9. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
10. LSU researchers awarded 1 of the largest NSF grants in Louisiana history
11. Vaccinex, Inc. Awarded Three Qualifying Therapeutic Discovery Project (QTDP) Grants Under the Patient Protection and Affordable Care Act of 2010 (PPACA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... ... July 18, 2017 , ... Nanomedical Diagnostics, ... development, announces the launch of a new NTA biosensor chip for use with ... study the kinetics of polyhistidine-tagged (His-tagged) molecules quickly and reliably. , “Recombinant ...
(Date:7/18/2017)... ... 18, 2017 , ... Allotrope Foundation won the 2017 in ... the Allotrope Framework for commercial use. , The Bio-IT World Best Practices Awards ... the critical role of information technology in modern biomedical research, but also to ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... analytical instruments announced the launch of its new line of Heavy-Duty Orbital Shakers ... models (both analog and digital) for laboratory applications. These shakers are ideal ...
(Date:7/16/2017)... ... July 16, 2017 , ... ... instruments announced the launch of its new line of Rocking and Waving Shakers ... waving shaker models (both analog and digital) for laboratory applications in a variety ...
Breaking Biology Technology:
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel ... came to the DERMALOG stand together with the Japanese Prime Minster Shinzo ... At the largest German biometrics company the two government leaders could see ... as well as DERMALOG´s multi-biometrics system.   Continue ... ...
Breaking Biology News(10 mins):